OPTIMIZATION OF THE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROPERTIES OF AN ANTI-ABETA ANTIBODY M266 FAB FRAGMENT VARIANT BY SITE-SPECIFIC PEGYLATION